(Q44473934)

3 December 2017

Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes (English)

1 reference

3 December 2017

0 references

0 references

0 references

0 references

0 references

4

1 reference

3 December 2017

Guenther Boden

1

1 reference

3 December 2017

Peter Cheung

series ordinal

2

1 reference

3 December 2017

Maria Mozzoli

series ordinal

3

1 reference

3 December 2017

language of work or name

1 reference

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

52

1 reference

3 December 2017

6

1 reference

3 December 2017

753-759

1 reference

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

In vivo and in vitro effects of antiinsulin receptor antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Measurement of size and turnover rate of body glucose pool by the isotope dilution method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Effects of therapy on the nature and quantity of fuels oxidized during diabetic ketoacidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Effect of hyperinsulinemia on urea pool size and substrate oxidation rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Effects of insulin on fatty acid reesterification in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

A novel serum protein similar to C1q, produced exclusively in adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Endogenous glucose production is inhibited by the adipose-derived protein Acrp30

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Modulation of insulin activities by leptin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Leptin impairs metabolic actions of insulin in isolated rat adipocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Leptin receptor action in hepatic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Leptin-replacement therapy for lipodystrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Regulation of glucose transport by pioglitazone in cultured muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

Troglitazone action is independent of adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900055-6

10.1016/S0026-0495(03)00055-6

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference